Anacalypsis Therapeutics Raises €300K Pre-Seed Led by Metavallon VC

Anacalypsis Therapeutics, an Athens-based biotechnology company, has raised €300,000 in Pre-Seed funding. The round was led by Metavallon VC, which is the sole investor listed for the financing. The funding date is September 21, 2026.

What the Company Does

Anacalypsis Therapeutics is developing precision, disease-modifying therapeutic strategies and biomarkers for Parkinson's disease and related neurodegenerative disorders.

Its lead program, AT001, is a stapled peptide designed to disrupt the LRRK2-FADD protein-protein interaction. The program is initially aimed at Parkinson's disease linked to pathogenic LRRK2 variants.

Leadership and Location

The company was co-founded by CEO Alexia Polissidis and CSO Hardy Rideout. Anacalypsis Therapeutics is incubated at the Athens LifeTech Park (ALTP) in Athens.

Deal Summary

Company: Anacalypsis Therapeutics
Sector: Biotechnology
Focus: Precision, disease-modifying therapeutics and biomarkers for Parkinson's disease and related neurodegenerative disorders
Lead Program: AT001, a stapled peptide targeting the LRRK2-FADD protein-protein interaction
Round Type: Pre-Seed
Amount Raised: €300,000
Funding Date: September 21, 2026
Lead Investor: Metavallon VC
Investors: Metavallon VC
Location: Athens, Greece
Incubation: Athens LifeTech Park (ALTP)

Why It Matters

The Pre-Seed round provides early capital to a company pursuing a targeted approach in neurodegeneration. Anacalypsis Therapeutics' focus on the LRRK2-FADD interaction places its lead asset in the space of genetically defined Parkinson's disease, specifically cases linked to pathogenic LRRK2 variants. The company's combined therapeutic and biomarker strategy reflects an effort to pair disease-modifying intervention with precision patient identification.

For observers tracking early-stage biotech in Greece, the involvement of Metavallon VC as lead investor signals continued venture interest in the Athens life sciences ecosystem, where Anacalypsis Therapeutics is incubated at the Athens LifeTech Park.

What Comes Next

With Pre-Seed funding in place, the company is positioned to advance its stated focus areas: precision therapeutic strategies, biomarkers, and its lead stapled peptide program, AT001. Further milestones, additional investors, and subsequent financing details have not been disclosed in the funding information available.